Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind Phase II Trial of Topical HDIT101 Versus Placebo in Patients With Chronic Recurrent HSV-1 Infection and Orolabial Lesion

NCT04539483 is registered in ClinicalTrials.gov with Heidelberg ImmunoTherapeutics GmbH as lead sponsor.

NCT NCT04539483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04539483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind Phase II Trial of Topical HDIT101 Versus Placebo in Patients With Chronic Recurrent HSV-1 Infection and Orolabial Lesion
Lead sponsor
Heidelberg ImmunoTherapeutics GmbH
Phase
Phase 2
Overall status
Terminated
Start date
October 8, 2020
Completion date
May 31, 2023
Enrollment
761 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

herpes labialis